Induction of apoptosis and CYP4A1 expression in Sprague-Dawley rats exposed to low doses of perfluorooctane sulfonate

Journal of Toxicological Sciences

Volumn 36, Issue 2, 2011, Pages 201-210

  Kim, Hyung Sub ^a   Kwack, Seung Jun ^a   Han, Eui Sik ^a   Kang, Tae Seok ^a   Kim, Seung Hee ^a   Han, Soon Young ^a  

^a Korea Food and Drug Administration   (South Korea)

Author keywords

Apoptosis; CYP4A1; General toxicity; Hepatotoxicity; PFOS

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CASPASE 3; CREATININE; CYTOCHROME P450 4A1; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; PERFLUOROOCTANESULFONIC ACID; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BASOPHILIA; CELL CULTURE; CELL SWELLING; CELL VIABILITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOTOXICITY; ERYTHROCYTE COUNT; FATTY LIVER; FEMALE; FIBROSIS; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KIDNEY; LEUKOCYTE COUNT; LIPID METABOLISM; LIVER GRANULOMA; LIVER HYPERTROPHY; LIVER NECROSIS; LIVER TOXICITY; LIVER WEIGHT; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; NICK END LABELING; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RAT; SEX DIFFERENCE; SPLEEN DISEASE; STAINING; THROMBOCYTE COUNT; TOXICOLOGY; TRIACYLGLYCEROL BLOOD LEVEL; URINALYSIS; UTERUS; WEIGHT REDUCTION; WESTERN BLOTTING;

RATTUS; RODENTIA;

EID: 79955445326     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.36.201     Document Type: Article

References (26)

1. 3M Company (1999): Fluorochemical use, distribution, and release overview. (A Report Prepared for the US EPA 1 March, 2000: EPA Docket # OPPT-2002-0043). St. Paul, MN: 3M Company.
2. Apelberg, B.J., Witter, F.R., Herbstman, J.B., Calafat, A.M., Halden, R.U., Needham, L.L. and Goldman, L.R. (2007): Cord serum concentrations of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in relation to weight and size at birth. Environ. Health Perspect., 115, 1670-1676.
3. Austin, M.E., Kasturi, B.S., Barber, M., Kannan, K., Mohan Kumar, P.S. and Mohan Kumar Sheba, M.J. (2003): Neuroendocrine effects of perfluorooctane sulfonate in rats. Environ. Health Perspect., 111, 1485-1489.
4. Berthiaume, J. and Wallace, K.B. (2002): Perfluorooctanoate, perfluorooctane sulfonate, and N-ethyl perfluoroctanesulfonamido ethanol; peroxisome proliferation and mitochondrial biogenesis. Toxicol. Lett., 129, 23-32.
5. Cui, L., Zhou, Q., Liao, C., Fu, J. and Jiang, G. (2009): Studies on the toxicological effects of PFOA and PFOS on rats using histological observation and chemical analysis. Arch. Environ. Contam. Toxicol., 56, 338-349.
6. Giesy, J.P. and Kannan, K. (2001): Global distribution of perfluorooctanesulfonate in wildlife. Environ. Sci. Technol., 35, 1339-1342.
7. Goldenthal, E.I., Jessup, D.C., Geil, R.G., Jefferson, N.D., Arceo, R.J. and Ruecker, F.A. (1978a): 90-day subacute rat study. Study No. 137-085. International Research and Development Corporation, Mattawan, MI. (U.S. EPA Docket No. 8(e)HQ-1180-00374.
8. Goldenthal, E.I., Jessup, D.C., Geil, R.G. and Mehring, J.S. (1978b): 90-day subacute rhesus monkey toxicity study. Study No. 137-092. International Research and Development Corporation, Mattawan, MI. (U.S. EPA Docket No. 8(e)HQ-1180-00374.
9. Hansen, K.J., Clemen, L.A., Ellefson, M.E. and Johnson, H.O. (2001): Compound-specific, quantitative characterization of organic fluorochemicals in biological matrices. Environ. Sci. Technol., 35, 766-770.
10. Hu, W., Jones, P.D., Upham, B.L., Trosko, J.E., Lau, C. and Giesy, J.P. (2002): Inhibition of gap junctional intercellular communication by perfluorinated compounds in rat liver and dolphin kidney epithelial cell lines in vitro and Sprague-Dawley rats in vivo. Toxicol. Sci., 68, 429-436.
11. Hu, X.Z. and Hu, D. (2009): Effects of perfluorooctanate and perfluorooctane sulfonate exposure on hepatoma HepG2 cells. Arch. Toxicol., 83, 851-861.
12. Johnson, G.W., Gilson, S.J. and Ober, R.E. (1979): Absorption of FC-143-14C in rats after a single oral dose, Riker Laboratoires Inc., St. Paul, MN.
13. Kannan, K., Franson, J.C., Bowerman, W.W., Hansen, K.J., Jones, P.D. and Giesy, J.P. (2001): Perfluorooctane sulfonate in fish-eating water birds including bald eagles and albatrosses. Environ. Sci. Technol., 35, 3065-3070.
14. Kannan, K., Crosolini, S., Falandysz, J., Oehme, G., Focardi, S. and Giesy, J.P. (2002): Perfluorooctanesulfonate and related fluorinated hydrocarbons in marine mammals, fishes, and birds from coasts of the Baltic and the Mediterranean Seas. Environ. Sci. Technol., 36, 3210-3216.
15. Kennedy, G.L.Jr., Butenhoff, J.L., Olsen, G.W., O'Conner, J.C., Seacat, A.M., Perkins, R.G., Biegel, L.B., Murphy, S.R. and Farrar, D.G. (2004): The toxicology of perfluorooctanoate. Crit. Rev. Toxicol., 34, 351-384.
16. Lau, C., Thibodeaux, J.R., Hanson, R.G., Rogers, J.M., Grey, B.E., Stanton, M.E., Butenhoff, J.L. and Stevenson, L.A. (2003): Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. II: Postnatal Evaluation. Toxicol. Sci., 74, 382-392.
17. Li, A.C. and Glass, C.K. (2004): PPAR-and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J. Lipid Res., 45, 2161-2173.
18. Maggiora, M., Oraldi, M., Muzio, G. and Canuto, R.A. (2010): Involvement of PPARα and PPARγ in apoptosis and proliferation of human hepatocarcinoma HepG2 cells. Cell Biochem. Funct., 28, 571-577.
19. Olsen, G.W., Burris, J.M., Burlew, M.M. and Mandel, J.H. (2003): Epidemic assessment of worker serum perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations and medical surveillance examinations. J. Occup. Environ. Med., 45, 260-270.
20. Qazi, M.R., Nelson, B.D., Depierre, J.W. and Abedi-Valugerdi, M. (2010): 28-Day dietary exposure of mice to a low total dose (7 mg/kg) of perfluorooctanesulfonate (PFOS) alters neither the cellular compositions of the thymus and spleen nor humoral immune responses: does the route of administration play a pivotal role in PFOS-induced immunotoxicity? Toxicology, 267, 132-139.
21. Seacat, A.M., Thomford, P.J., Hansen, K.J., Olsen, G.W., Case, M.T. and Butenhoff, J.L. (2002): Subchronic toxicity studies on perfluorooctanesulfonate potassium salt in cynomolgus monkeys. Toxicol. Sci., 68, 249-264.
22. Seacat, A.M., Thomford, P.J., Hansen, K.J., Olsen, G.W., Case, M.T. and Butenhoff, J.L. (2003): Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats. Toxicology, 183, 117-131.
23. Shabalina, I.G., Panaretakis, T., Bergstrand, A. and DePierre, J.W. (1999): Effects of the rodent peroxisome proliferators and hepatocarcinogen, perfluorooctanoic acid, on apoptosis in human hepatoma HepG2 cells. Carcinogenesis, 20, 2237-2246.
24. Thibodeaux, J.R., Hanson, R.G., Rogers, J.M., Grey, B.E., Barbee, B.D., Richards, J.H., Butenhoff, J.L., Stevenson, L.A. and Lau, C. (2003): Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. I: maternal and prenatal evaluations. Toxicol. Sci., 74, 369-381.
25. Vanden Heuvel, J.P., Thompson, J.T., Frame, S.R. and Gillies, P.J. (2006): Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-alpha,-beta, and-gamma, liver X receptor-beta, and retinoid X receptor-alpha. Toxicol. Sci., 92, 476-489.
26. Yahia, D., Tsukuba, C., Yoshida, M., and Sato, I. and Tsuda, S. (2008): Neonatal death of mice treated with perfluorooctane sulfonate. J. Toxicol. Sci., 33, 219-226.